Close Menu

FIND

The firm launched a CE-IVD marked test for extremely drug-resistant TB and expects to incorporate the multiplexing technology in other assays.

FIND will use the funding to support the development of rapid tests, especially in low- and middle-income countries.

The Foundation for Innovative New Diagnostics is tracking commercial coronavirus diagnostics development project, with the goal of guiding procurement.

The two organizations are collaborating to perform a standardized evaluation of currently available molecular diagnostic tests to assess test performance.

FIND also announced support for projects from Axxin and DNC Dx for point-of-care detection of sexually transmitted infections.  

The project, called Seq&Treat, will be implemented in Brazil, China, Georgia, India, and South Africa starting in October.

The test for P. vivax-associated malaria was developed with support from FIND and will be distributed by Human Diagnostics Worldwide.

The firm has been placing point-of-care systems primarily in the private sector, but may have increased access once it completes WHO prequalification review.

FIND will lead evaluation studies in Cameroon and Georgia between September 2018 and May 2019 to confirm the assay's diagnostic accuracy and commercial utility.

The study is the first to demonstrate the design features and operational characteristics of Cepheid's Xpert MTB/RIF Ultra assay.

Pages

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.